ImmuneOncia Therapeutics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	8,238	8,226	20,957	26,730	36,320
Short-Term Investments	15,200	3,100	5,000	-	6,000
Cash & Short-Term Investments	23,438	11,326	25,957	26,730	42,320
Cash Growth	106.93%	-56.36%	-2.89%	-36.84%	104.10%
Accounts Receivable	-	421.83	11	633.65	-
Other Receivables	128.37	7,709	172.13	202.16	41.53
Receivables	128.37	8,131	183.13	835.81	41.53
Prepaid Expenses	2,475	297.34	376.95	520.18	232.62
Other Current Assets	465.54	107.93	118.97	884.02	72.89
Total Current Assets	26,506	19,863	26,636	28,970	42,667
Property, Plant & Equipment	649	494.54	892.1	547.33	997.96
Other Intangible Assets	4,503	4,908	5,429	5,987	6,503
Other Long-Term Assets	1,487	930.02	838.32	188.36	932.89
Total Assets	33,146	26,195	33,795	35,693	51,101
Accrued Expenses	138.88	137.63	103.34	154.4	128.24
Current Portion of Leases	54.98	51.05	50.11	98.69	216.39
Current Unearned Revenue	1,950	1,950	1,950	1,950	6,902
Other Current Liabilities	2,115	4,354	1,268	1,646	1,578
Total Current Liabilities	4,259	6,493	3,372	3,850	8,824
Long-Term Leases	14.55	44.01	86.83	24.27	98.24
Pension & Post-Retirement Benefits	139.2	15.06	14.27	-	184.09
Other Long-Term Liabilities	317.13	219.18	236.63	84,226	101,526
Total Liabilities	4,730	6,771	3,710	88,100	110,633
Common Stock	37,083	36,365	26,896	26,141	25,503
Additional Paid-In Capital	115,752	79,021	35,292	28,046	22,148
Retained Earnings	-138,091	-110,721	-105,016	-113,921	-110,518
Comprehensive Income & Other	13,672	14,759	8,637	7,326	3,336
Total Common Equity	28,415	19,424	-34,192	-52,407	-59,532
Shareholders' Equity	28,415	19,424	30,086	-52,407	-59,532
Total Liabilities & Equity	33,146	26,195	33,795	35,693	51,101
Total Debt	69.53	95.06	136.94	122.97	314.63
Net Cash (Debt)	23,368	11,231	25,820	26,607	42,005
Net Cash Growth	108.06%	-56.50%	-2.96%	-36.66%	103.58%
Net Cash Per Share	333.06	199.46	492.28	510.53	904.13
Filing Date Shares Outstanding	73.96	56.31	52.45	52.12	46.46
Total Common Shares Outstanding	73.96	56.31	52.45	52.12	46.46
Working Capital	22,247	13,370	23,264	25,120	33,842
Book Value Per Share	384.21	344.97	-651.90	-1005.59	-1281.39
Tangible Book Value	23,913	14,516	-39,621	-58,394	-66,035
Tangible Book Value Per Share	323.33	257.81	-755.41	-1120.48	-1421.36
Machinery	1,797	1,514	1,443	1,173	1,148

Source: S&P Global Market Intelligence. Standard template. Financial Sources.